Oncology Drugs - Tanzania

Tanzania

The projected revenue in the Oncology Drugs market in Tanzania is set to reach US$36.91m in 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 7.61%, thus leading to a market volume of US$53.27m by 2029.
When compared globally, United States will generate the highest revenue, amounting to US$103,900.00m in 2024.
Tanzania's oncology drug market is witnessing a surge in demand due to an increasing prevalence of cancer cases in the country.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for oncology drugs in Tanzania has been on the rise in recent years.

Customer preferences: The growing awareness of cancer and its treatment options, coupled with an increase in the number of cancer cases, has led to a rise in demand for oncology drugs in Tanzania. Patients are becoming more informed about their treatment options and are seeking more effective and affordable medication.

Trends in the market: One of the major trends in the Tanzanian oncology drugs market is the increasing availability of generic drugs. This has made cancer treatment more affordable for patients who would otherwise not be able to afford it. Additionally, the government has been investing more in the healthcare sector, which has led to the establishment of more oncology treatment centers across the country.

Local special circumstances: The Tanzanian oncology drugs market is unique in that there is a high prevalence of HIV/AIDS, which increases the risk of cancer. This has led to an increase in demand for oncology drugs that can treat both cancer and HIV/AIDS. Additionally, the lack of medical infrastructure in some parts of the country has led to a rise in demand for mobile oncology clinics that can provide cancer treatment to patients in remote areas.

Underlying macroeconomic factors: The Tanzanian economy has been growing steadily in recent years, which has led to an increase in disposable income and an expansion of the middle class. This has led to an increase in demand for healthcare services, including oncology drugs. Additionally, the government has been investing more in the healthcare sector, which has led to an increase in the availability of oncology drugs and treatment centers across the country.In conclusion, the Tanzanian oncology drugs market is growing due to the increasing demand for cancer treatment, the availability of generic drugs, the establishment of more treatment centers, the high prevalence of HIV/AIDS, and the growing economy.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.